Robert Risinger, MD

Chief Medical Officer
BioXcel Therapeutics

TBD

Poster(s):

• (122) Sublingual Dexmedetomidine for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: Effect Size and Pooled Efficacy